Soligenix has entered a collaboration agreement with University of Hawaii at Manoa (UH Manoa) and Hawaii Biotech (HBI) to develop a heat stable subunit Ebola vaccine.
John A Burns School of Medicine’s (JABSOM), tropical medicine, medical microbiology and pharmacology assistant professor Dr Axel Lehrer will also be a part of the collaboration to develop vaccine.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Dr Lehrer is a co-inventor of the Ebola vaccine with HBI that shown proof-of-concept efficacy with subunit Ebola vaccines in non-human primates.
As per terms of the feasibility agreement, Soligenix will assess its proprietary vaccine thermostabilisation technology ThermoVax to stabilise components of the vaccine. The technology is licenced from the University of Colorado.
The collaboration will produce a thermostable Ebola vaccine for worldwide distribution that does not require cold storage and will initially focus on a single protein subunit antigen of the potential virus treatment.
Dr Lehrer said: "There is a great need for a thermostable Ebola vaccine, particularly in areas of the world where filoviruses are endemic and the power supply uncertain."
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThermoVax previously demonstrated to enhance thermostability of both ricin (RiVax) and anthrax (VeloThrax) subunit vaccines.
The technology has been designed to eliminate the standard cold chain production, distribution and storage logistics required for most vaccines.
ThermoVax technology uses precise lyophilisation of protein immunogens with conventional aluminum adjuvants in combination with secondary adjuvants for rapid onset of protective immunity with the fewest number of vaccinations.
Image: Electron micrograph of an Ebola virus virion. Photo: courtesy of CDC/Cynthia Goldsmith.
